<DOC>
	<DOC>NCT02383563</DOC>
	<brief_summary>This proposal seeks to assess the impact of 24 weeks of metformin on non-calcified plaques and calcified plaques assessed by coronary CT angiography, and on whether these changes can be explained by metformin-induced phenotypic and secretory changes of monocytes.</brief_summary>
	<brief_title>Metformin for HIV Inflammation</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>HIV+ on suppressive ART stable for &gt; 1 year Age &gt; 45 years Ability and willingness to provide written informed consent Uncontrolled chronic medical condition or cancer Acute illness within 2 weeks of entry Diagnosis of diabetes or impaired fasting glucose Chronic diarrhea Known hypersensitivity or contraindication to metformin use Hepatitis C coinfection Serum B12 level below the reference normal range as listed by the commercial laboratory (Diagnostic Laboratory Services) Pregnancy, or intent to become pregnant Any immunomodulator, HIV vaccine, any other vaccine, or investigational therapy within 30 days of study entry. Current or past history of coronary artery disease or congestive heart failure Resting heart rate &gt; 100 beats/min Presence of conduction abnormalities or pathologic arrhythmia on EKG The following lab values: Hemoglobin &lt; 9.0 g/dL; Absolute neutrophil count &lt; 1000/μL; Platelet count &lt; 50,000/μL; and AST (SGOT) and ALT (SGPT) &gt; 5x ULN Calculated creatinine clearance (Cockcroft and Gault) &lt; 60 ml/min Patients over 450 lbs History of iodine allergy or Xray contrast allergy History of allergy to metoprolol Active or recent past history (within past 2 years) of illicit substance or alcohol use or abuse which, in the judgment of the Investigator, will interfere with the patient's ability to comply with the protocol requirements Patients in whom there are other reasons that the CAC/CTA procedure is contraindicated or who are at higher risk of adverse events Patients, who, in the opinion of the Investigator, are unable to comply with the dosing schedule and protocol evaluation or for whom the study may not be advisable</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>